Biocartis Group 과거 수익 실적

과거 기준 확인 0/6

Biocartis Group의 수입은 연평균 -7.1%의 비율로 감소해 온 반면, Medical Equipment 산업은 수입이 연평균 1.1%의 비율로 감소했습니다. 매출은 연평균 16.2%의 비율로 증가해 왔습니다.

주요 정보

-7.1%

수익 성장률

-2.2%

EPS 성장률

Medical Equipment 산업 성장	4.3%
매출 성장률	16.2%
자기자본 수익률	n/a
순이익	-111.6%
최근 수익 업데이트	30 Jun 2023

최근 과거 실적 업데이트

Recent updates

수익 및 비용 분석

Biocartis Group 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

DB:8XB 수익, 비용 및 수입 (EUR Millions )
날짜	수익	수익	G+A 비용
30 Jun 23	61	-68	37
31 Mar 23	59	-67	37
31 Dec 22	58	-65	37
30 Sep 22	58	-64	36
30 Jun 22	59	-63	35
31 Mar 22	57	-67	34
31 Dec 21	55	-71	32
30 Sep 21	58	-70	32
30 Jun 21	61	-69	32
31 Mar 21	58	-66	31
31 Dec 20	56	-63	30
30 Sep 20	47	-64	31
30 Jun 20	38	-66	31
31 Mar 20	38	-65	32
31 Dec 19	38	-64	32
30 Sep 19	35	-60	30
30 Jun 19	33	-56	28
31 Mar 19	31	-52	25
31 Dec 18	29	-48	23
30 Sep 18	29	-44	22
30 Jun 18	29	-40	21
31 Mar 18	26	-41	20
31 Dec 17	23	-42	18
30 Sep 17	19	-46	17
30 Jun 17	14	-50	16
31 Mar 17	14	-50	16
31 Dec 16	14	-50	16
30 Sep 16	14	-48	16
30 Jun 16	14	-47	17
31 Mar 16	15	-43	16
31 Dec 15	15	-40	15
30 Sep 15	15	-35	14
30 Jun 15	15	-30	13
31 Mar 15	13	-29	12
31 Dec 14	10	-29	10
31 Dec 13	12	-27	8
31 Dec 12	6	-37	7

양질의 수익: 8XB 은(는) 현재 수익성이 없습니다.

이익 마진 증가: 8XB 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: 8XB 은(는) 수익성이 없으며 지난 5년 동안 연간 7.1% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 8XB 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: 8XB 은(는) 수익성이 없어 지난 해 수익 성장을 Medical Equipment 업계( 10.1% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: 8XB 의 부채가 자산을 초과하므로 자기자본수익률을 계산하기 어렵습니다.

Biocartis Group 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

First half 2023 earnings released

Biocartis Group NV to Report First Half, 2023 Results on Sep 26, 2023

Full year 2022 earnings released: €0.79 loss per share (vs €1.24 loss in FY 2021)

Full year 2022 earnings released: €0.79 loss per share (vs €1.24 loss in FY 2021)

Biocartis Group NV to Report Q1, 2023 Results on Apr 20, 2023

First half 2022 earnings released: EPS: €0 (vs €0.65 loss in 1H 2021)

Recent updates

Biocartis Group Ordinary Shares to be Deleted from OTC Equity

Biocartis Group NV Presents Four Abstracts Showing Excellent Data for Idylla at European Society of Molecular Oncology Congress

First half 2023 earnings released

Biocartis Appoints New Medical Advisory Board (Mab) of Renowned Practice Leaders

Biocartis Group NV to Report First Half, 2023 Results on Sep 26, 2023

Biocartis Group NV Appoints George Cardoza as Chief Financial Officer, Effective 7 August 2023

Biocartis Group NV Announces Resignation of Jean-Marc Roelandt as CFO

Full year 2022 earnings released: €0.79 loss per share (vs €1.24 loss in FY 2021)

Full year 2022 earnings released: €0.79 loss per share (vs €1.24 loss in FY 2021)

Biocartis Group NV Announces the Launch of the First Assay Developed With the New Idylla™ Flex Technology

Biocartis Group NV has completed a Follow-on Equity Offering in the amount of €25.107699 million.

Insufficient new directors

Biocartis Group NV Announces New Idylla™ EGFR Study Shows Reduction of Time-To-Treatment by 48% for Lung Cancer Patients

Biocartis Group NV Announces New Idylla™ EGFR Study Shows Reduction of Time-To-Treatment by 48% for Lung Cancer Patients

Biocartis Group NV to Report Q1, 2023 Results on Apr 20, 2023

First half 2022 earnings released: EPS: €0 (vs €0.65 loss in 1H 2021)

Biocartis Group NV Provides Earnings Guidance for 2022

Biocartis Group NV Obtains ISO 27001 Certification for Information Security Management

Biocartis Group NV Announces Launch of its Rapid CE-marked IVD Idylla GeneFusion Panel for Fast Treatment Decisions in Lung Cancer

Biocartis Group NV announces New Study Led by Memorial Sloan Kettering Cancer Center (NY, US) Shows Idylla™ Genefusion Assay Enables More Rapid Screening of Targetable Fusions Compared to Routine Methods

Insufficient new directors

Biocartis Group NV Reconfirms Earnings Guidance of 2022

Full year 2021 earnings released: €1.24 loss per share (vs €1.11 loss in FY 2020)

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Biocartis Group NV Provides Earnings Guidance for the Year 2022

Biocartis Group NV Announces Publication of Large New Study Comparing the Difference in Turnaround Time Between In-House Automated Rapid Pcr3-Based EGFR Analysis and Next-Generation Sequencing

Insufficient new directors

Biocartis’ Idylla™ SARS-CoV-2 Testing Successfully Detects Omicron Variant

Biocartis Group NV Announces Restart of Its High-Throughput Cartridge Manufacturing Line

Biocartis Group NV Receives EUR 1.4 Million Grant to Support Development of New Idylla™ Technology

Biocartis Group NV Reconfirms Production Guidance of 2021

Full year 2020 earnings released: €1.11 loss per share (vs €1.14 loss in FY 2019)

New 90-day low: €4.31

Full year 2020 earnings released: €1.11 loss per share (vs €1.14 loss in FY 2019)

Revenue beats expectations

Biocartis Group NV Announces Ten Idylla™ Studies to be Published at Virtual AMP (US) Annual Meeting

Biocartis Group NV Announces Publication of Large Multi-Center Comparison Study with Idylla™ MSI Assay

Biocartis Group NV to Report Q3, 2021 Results on Nov 10, 2021

Biocartis and Geneprodx to Collaborate on Fully Automated Thyroidprint Test on Idylla

Biocartis Group NV Announces Partnership with Endpoint Health to Develop Novel Companion Diagnostic in Critical Illness

New 90-day low: €3.92

Biocartis Group Nv Announces Market Release of Septicyte® Rapid Test on Idylla™

First half earnings released

Biocartis Group NV to Report Fiscal Year 2020 Final Results on Apr 01, 2021

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기